Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It depends on who you are...
If you've flipped this piece of crap over and over and over again from 20 to 50 cent...
You probably would have made a small fortune.
If you are anyone of the insiders of the company....
You have secured yourself millions of dollars in salary/bonuses/stock options...etc etc.
If you are at the University Of Florida....
You have used the public's money to advance your lab classes and purchase of new lab equipment over the years that will be utilized decades beyond the ultimate bankruptcy of Cannabix Technologies Inc.
If you are a newbie who bought into the latest news release about testing...
Buckle Up! You'll get those same news releases as those from the previous 9 years.
If you are none of the above...
I'm clueless as to why you're clueless.
Rhetorically speaking of course.
M$
Moreau (CEO) handed you a paltry 3 additional shares (3%) back for every one hundred shares pulled from you in the last reverse split (100:1).
His "reasoning" is to increase volume so you can flip your little share count.
Among a slew of other failings, your CEO has absolutely no clue of how to anticipate market reactions.
Like the time he kept halting the market for a bunch of dumb "news releases" that crippled momentum and decreased the value of shares.
Did he really think handing you back 3% of your shares to flip would make any significant difference in average daily volume with less than 10M outstanding shares at play?
At every turn of decision that guy comes up short in what he would surely profess to be a good intent effort.
It's a show of pure madness from one decision to the next in a very long line of crazy antics in Clown Town.
20 cent trading by summer with at least 3X dilution for any chance at starting a standalone Chronic Cough clinical trial.
M$
All the trading platforms algorithms are overwhelmed by the continuous flip flop back forth reverse forward splits. They all came out with a joint statement saying they've never seen anything like it in the penny stock world. They can only compare it to the 1930's boom bust era when the Barnum & Bailey - Ringling Brothers Circus Act kept going up and down with the price of tickets to see the Greatest Clown Show On Earth. Back then the ups and downs observed by the business community led to the idea of the worlds first rollercoaster ride including first ever leak proof barf bags. Stores the world over now use those same bags for all your in-store purchases. Who knows what new type of bafoonery will be inspired by the ongoing antics of Algernon Pharmaceuticals Inc? One can only guess it'll likely top TikTok.
Just ^acts.
M$
Yeah, the DMT "story" was snatched out from under shareholders old and new. Without doing gymnastics mathematics have you any idea how many shares of the "private" company you supposedly own based on your shares of AGN/PF? The flips and flops throughout the Algernon story is staggering. I expect the same fumbling and bumbling to continue into the foreseeable future. The latest shtick about the private company is it targets even less informed people (kids with credit cards) who don't really follow stocks at all. That's saying a lot considering Moreau has called AGN/PF investors stupid on more than one occasion. Management knows the pennyland crowd has had enough of their nonsense, so they needed to go elsewhere for any chance at raising money to move forward. Management still has the monumental task of raising money for AGN/PF to conduct ANY Phase 2 clinical trial moving forward. Algernon Pharmaceuticals is truly on it's last leg to get some positive data or everything will go bust, I like Shell's math. It goes even further with showing just how much you have lost over the years going back to the first reverse split immediately followed up with 100% dilution for the failed COVID-19 studies (South Korea/Romania). I still predict AGN/PF to be a 20 cent trade at best by this coming summer. Management is a collective of natural born penny stock company losers. Even the prior company that Board of Director, Mark Williams comes from is flailing around with a botched Phase 2 study that they cannot get back on track with the FDA. Algernon Pharmaceuticals has the Pennyland Plague.
Spreading The Love Circa 2016
M$
The legalization of recreational marijuana will have been in place across North America going on 10 years (a decade). Society is not clamouring for a roadside marijuana device in any state in the land. The only people still making a fuss is those with time/money tied up in an effort to create a market for such a device if it's ever deemed legal and effective in real world practicality. One must think critically as to why there isn't a single big name tech company interested in pursuing such a device. If it were you would've heard of it by now. No big names exist. Not one. You only have mom and pop sweat shop operators in the space. The Cannabix schtick is one of the oldest roadshows around. Thus far, offering nearly 9 years worth of testing testing and more testing. Don't expect that story to ever change as the stock bounces back and forth from 20 cent to 50 cent until the masses (including newbie investors) finally catches onto the fact there is no there there for a marijuana breathalyzer. Period.
M$
A “40% Gain” according to who?
Canadian Securities Exchange: AGN ^ 31.61%
CEO.CA: AGN ^ 32.9%
NASDAQ: AGNPF ^34.29%
Yahoo Finance: AGNPF ^37.17%
Investorshub: AGNPF ^38.39%
I find no reputable financial outlet reporting a 40% Gain.
Real World Observation: One must actually sell a position to realize any perceived gain. In this case there is no gain for 2:1 and 100:1 pre-reverse split shareholders. That’s just one harsh fact. Another harsh fact is the lack of volume means the total number of shares traded this past Friday on CSE & OTC was the equivalent of Eight Hundredths Of 1% (.0008%) of the total float of 9,653,724 outstanding shares.
If you recall...
Your 2:1 reverse split was the bargain with the devil to buy Nash Pharmaceuticals, then spun on a dime to pursue two demonstrably failed COVID-19 clinical trials claimed to have a 55% and/or 65% Chance Of Success.
Your 100:1 reverse split was claimed to be for an uplist to NASDAQ.
Your 4:1 forward split is claimed to be an incentive to increase liquidity/volume.
Moving forward, the average number of trading days per year on NYSE/NASDAQ is Two Hundred & Fifty Two Days (252). Hence, if all shares were sold equally based on an individual's perceived “40% Gain”, it would take you approximately Five Years (5) to sell all of your shares. That’s the reality you’re dealing with with ultra low volume. The”market cap” is but one number in an equation that's inherently more complex for any so-called investor/flipper to grapple with in pennyland.
Rebut it but it aint seriously rebuttable.
$7.50 US is now the average pre|post reverse|forward split break even price per share.
$15 US is now the average break even price for all shares held since Breathtec Biomedical (2016-2018).
M$
OAN, This Is Literally The Definition Of A Hail Mary News Release:
March 2, 2023 - "Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board"
_______
AFL (Algernon Football League) Shows NFL All Their Dirty Little Tricks:
Scrimmage
The "difference" is everyone knows the difference and Friday's nano nano cap pump was all fluff. As of now the stock is still at 90% loses pre & post 100:1 reverse split. Thus, my previous post is on point. As most of them.usually are and original thoughts. I stay on offense without trying to be offensive.
One other thought:
The stock was trading in the 30 cent range BEFORE the 2:1 reverse split.
The stock was trading in the 30 cent range BEFORE the 100:1 reverse split.
The stock for one day thus far has traded in the 30 cent range since the 4:1 forward split.
What part of the Algernon Pharmaceuticals hellscape story have I missed?
No fluff. Just facts.
M$
Had the 4:1 forward split not taken effect yesterday, OTC would have traded 80 shares (EIGHTY). Which means, among other dismal indicators, there would've been ZERO change in the close price from this past Thursday, March 2, 2023 @ .2825 (forward split adjusted price).
Less than $125 US pushed the stock up by 10 cents (37%). In the Penny World, I guess that means Algernon Pharmaceuticals is on the road to recovery from a years-long tour of Dante's Inferno? Facetiously speaking of course.
Bedeviling @ Best
M$
4:1 Forward Split to increase "Liquidity" my @ss!!! LOL
Moron knew the stock was headed for under $1 in short order. So, instead of taking another historic blow to his failed face, he decided to force a trade under $1 as if but for....
Moron is a full blown loser whose tried and troubled tactics are transparent if one simply opens their eyes. That guy is a failed leader by every measure. He runs companies completely into the ground. That's his specialty.
Breathtec Boimedical - Algernon Pharmaceuticals - Algernon Neuroscience has zero differences between them. Same "CEO" same lame blame game results year after year.
Dudes dilution schemes are Epic!!!!
You're in penny world forever with these peopje at the helm. That's where their scheming skills shine the most with zero accountability. Further dilution is eminent if they can get the usual suspects to buy into another attempted pump/dump scheme.
However, the Algernon Pharmaceuticals story has become ICE COLD as current investors have finally awakened to the sheer ignorance on display at their virtual corporate office(s) in Vancouver.
You will be trading a 10 cent stock soon enough. It's right around that number that will likely bring back King Flipper and maybe a 25% hold by AlphaNorth. If not, bankruptcy awaits.
The Chronic Cough trial is dead in the water. You'll need 4 to 5 times the market cap of the company to run any serious Phase 2b clinical trial outside of Australia. By the time that happens your share count will be north of 50M shares outstanding if not bankruptcy.
.
Eitherway, the only story you'll keep hearing about is the subsidiary that you can't even point to shares to in your account. Yeah, fuzzy math. Meanwhile, you're the one paying for all of its overhyped pennyland advertising.
The show must go on...
Corporate Entertainment
M$
AGNPF: 10 Cent Trade By Summer. EOM M$
The only true story to tell about Algernon Pharmaceuticals is the roof is on fire.
Your "CEO"' has now masterfully burned down the walls of yet another penny stock company.
You are now back to penny world officially and permanently pending a potential bankruptcy.
2/1 reverse split - 100/1 - reverse split - 25/1 forward split. Confused yet?
Don't be...all roads lead to Dante's Inferno @ Algernon Pharmaceuticals Inc.
The Roof...The Roof...The Roof Is On Fire...
M$
Outro
The only thing coming out of the "Private" company Algernon Neuroscience (which is merely snatching the lame@ss DMT angle out of your control) is the "CEO" and Cohorts have likely doubled thier annual compensation packages. You have been royally screwed.
$30 Break Even. Sub $1 By Summer. EOM
M$
I Report...
You Decide...
IMO, one should be considered woefully misinformed if one can't see how ineffective marketing is driving the bus towards every fire sale of shares.
The CEO is hellbent on prancing around like a peacock with the exact same ineffective pennyland marketing media.
You know the names of all of them by now under the Circus Tent Bigtop. None of them are worth spending money on for same ole same ole results.
Look at the overall percentage of spend on marketing. It's the overwhelming driver of Algernon's consistent bottomline poverty.
Then look at your stock price from quarter to quarter. IMO, you continue getting ripped off royally.
My best guess is Christopher Moreau (CEO) spends a lot of his time looking at himself in the vanity mirror.
The question is does he see what everyone else sees?
Due Diligence...
M$
tcm55 Financing the DMT Trial is from selling 37% of AGNNeuro shares. So Yes, I believe that is a fair deal for AGN shareholders.
M$ It does not address the question(s) I asked. Which is regarding advertising for the DMT program that is now in the hands of a SUBSIDIARY company of Algernon Pharmaceuticals Inc. As I've said, AGN/PF shareholders are paying 100% of the cost of advertising for Algernon Neuroscience with a share structure independent of the shares you may own. Diluting one group of shareholders to prop up another group of shareholders. That's the same type of dilution scheme Kulwant Malhi orchestrated by flipping millions of AGN shares for Growmax Resources shareholders. All while Moreau (CEO) and Williams (CSO) worked for Malhi at First Responder Technologies, now a bankrupt company. Let me guess, ^that's just fine and dandy as well? However, it is Algernon Pharmaceuticals after-all. There's ample historical reasons the stock price remains in the sewer beneath ground level no matter what comes out of the CEO’s mouth next.
tcm55 COVID was scammed by Phiser/Fousi and even MDNA was pushed aside. All repurposed drugs from several companies were forced to do Trials while Phiser was given a pass and subsidized Trials/research. So inaccurate question IMO., but there are many articles on these subjects.
M$ Sir, that honestly sounds like a theory that I see no point in getting muddled in.
tcm55 Ifenprodil did not fail it's CT and there were significant benefits proven including IL-6 for COVID patients and CC reduction / slowing rate of IPF in that 2nd Phase 2 CT for Ifenprodil. i.e. a Phase 2b CT for CC this summer/asap...
I would talk about Cancer But Cancer use for Ifenprodil is another repurposed direction still being applied for ODD/IND status at the FDA and a current CT is not being planned. Maybe later as with the CKD drug. So Yes.
...(I have discussed Cancer in private, confidentially, but I dislike malfeasant sour grapes, so that's over) ....!!
M$ The bottomline is the COVID-19 study DID NOT advance to Phase III because of weak data. Hence, the study was a failure. If you don’t believe me ask expert analyst Andre Uddin (Algernon Pharmaceuticals lone analyst) who covers the stock.
“Commenting on the results, Uddin wrote, “The lack of a dose-dependent effect in a clinical trial normally suggests poor efficacy of a compound. AGN disclosed 40 mg ifenprodil did not show any effects in this study while the 20 mg dose demonstrated some trends. Based on the lack of dose response, we unfortunately would not expect this indication to be advanced.”
https://www.cantechletter.com/2021/04/take-a-pass-on-algernon-pharmaceuticals-says-mackie/#
M$ Better yet, have Algernon Pharmaceuticals release the written recommendations given to them by the FDA. My best guess is a move to Phase III would have been catastrophically stupid and futile.
tcm55 Accusing the AGN CEO of being a drunk is a TOS violation, IMHFO…
M$ It’s a typo. Drunk should have read as drum…beating drum…not beating drunk. Get it now?
tcm55 If you dont like the company;s format for repurposed drugs then sell the rest of any shares you may still have and move on. I plan to buy more.
M$ I’ve heard it all before.
tcm55 Taking comments out of context, ie Shell, is unfair IMO
M$ You have exactly what was posted by shell in BLACK and WHITE. Ask him or anyone else if they think I somehow misinterpreted the facts.
IMO, there remains ZERO legitimate rebuttals to ANY of the concerns I’ve raised regarding Algernon Pharmaceuticals Inc.
Peace
The following is my reply to your concerns about my last two posts. The first topic being Christopher Moreau calling all shareholders stupid.
If you take what you stated regarding owning approx 65% of DMT as AGN/PF shareholder,,,the question remains how much of Moreau’s prancing peacock PR campaign is Algernon Neuroscience footing the bill? You think it’s OK to own 65% of something and pay 100% of the cost?
YES or NO?
The second topic being Christopher Moreau’s claim that the demonstrably failed COVID-19 Phase 2b “multinational” clinical trial had a 65% Chance Of Success...the question remains will Moreau begin spouting and shouting from pennyland rooftops the DMT program will have a 65% Chance Of Success at Phase 2? That’s assuming they will get beyond Phase 1 of the clinical trial process.
YES OR NO?
The same question can be asked of ANY of the drugs in the pipeline. When does the 55% and/or 65% Chance Of Success become the beating drunk of corporate officers in the know?
If there is any dispute regarding the above 65% number in the first and second instance, please try to address it specifically.
Meanwhile, I assume shell3 would have no dispute about Moreau’s BETTER THAN BACCARAT ODDS for Algernon Pharmaceuticals ``Repurposed Drugs' ' and Non Repurposed Drugs in its pipeline.
According to Algernon leadership...You Get A Car and You Get A Car...!!!
Here’s a post from shell3 (a longtime Moderator here) after observing one of the Biopub Webcasts during the height of the COVID-19 Pandemic:.
shell3 - Friday, February 28, 2020 12:41:10 PM
Anyone here know if the CEO has pitched a 65% Chance Of Success for standalone Chronic Cough the same as he did for COVID-19?
Where's all the Biopub boys to weigh in these days?
My best guess is the CEO will await the results of the DMT Phase 1 before making a move on the market to claim yet again a 65% Chance Of Success at Phase 2.
Yeah, you'll hit it rich alright....
The CEO claims all your woes are because Penny Stock Investors @ CSE & OTC are stupid people. The CEO has stated the same thing in the recent past then retracted. Says he was misunderstood. Yet, he repeated it again. Hence, the mangled mumbo jumbo mantra about existing shareholders not understanding the value of the company. More specifically, not understanding their perceived 20M U$ valuation of the Phase 1 DMT angle that was decoupled from your narrative. Yeah, the CEO is out and about spouting to the rooftops about DMT.
Meanwhile, you're the ones stuck paying the bills for that ineffective mess/aging as Algernon Neuroscience sits back and watches you spend your way to another fire sale to raise a few pennies from pennyland pirates as usual. You continue to get played like all day suckers 24/7/365. Does the dumb-dumb excuse the CEO has leveled against shareholders does have some merit? You be the judge. However, this is Christopher Moreau's (CEO @ Algernon Pharmaceuticals Inc.) direct leadership performance since 2018. It's not a snapshot quick fix. It's a motion picture disaster in a long descent into Dante's Inferno.
See all time losses of 97.85%. You're less than 3% away from total bankruptcy.
THE MONEY SHOT
I hear footsteps...
electratect.com/technology
My posts are not about the whims of anyone's trading habits in Pennyworld. My posts are about the ever flailing direction of a publicly traded company (Algernon Pharmaceuticals Inc.) and the harsh and warranted critique that comes with it. I have read zero legitimate rebuttals anywhere on the World Wide Web.
Period
M$
Flip Flop Decisions Remains @ The Helm
@ Radius Research the Interviewer hits the correct number of 150% Dilution with a capital raise of 10M USD. Then turns right around and says a capital raise of 10M USD through Algernon Neuro only requires roughly a 30% dilution of Algernon Neuro. That's fundamentally inaccurate. Moreau said they value Algernon Neuro at 20M USD. You can't raise 10M USD without diluting 50% (Half) of Algernon Neuro to would be "private" investors. Just because you say something over and over again doesn't make it less false. It would appear that the gaslighting never ends.
To date, you are funding the blitz of pump action to boost the private company and simultaneously being told by Christopher Moreau you're likely better off investing in Algernon Neuro because Algernon Pharmaceuticals investors are basically incompetent. I'm of the belief there is some there there from top to bottom in regards to all things Algernon Pharmaceuticals. You're now officially the stepchild here. Worse case scenario, Algernon Pharmaceuticals goes bust in the next couple few years. Hence, the push to get you to buy into the "private" company, managed by the same decision making people, before AlphaNorth figures out a way to buy up those shares as well, if not already.
Speaking of past practice. It is the past practice of your leaders to pull the rug out from under you while claiming it's for your own good. Look back at what happened to your FAIMS agreement with the University of Florida. Moreau surrendered the agreement after years of financial partnership with Cannabix Technologies Inc. Algernon Pharmaceuticals footed 50% of the cost to push the FAIMS tech forward. If you look at Cannabix website they now tout a FAIMS device for researchers and the like to explore whatever their heart desires. That is the exact same strategy Algernon Pharmaceuticals (formerly Breathtec Biomedical) was pursuing to not be in conflict with Cannabix's pursuit of controlled substances. In the end, Algernon Pharmaceuticals came away from that deal with absolutely nothing to show for its efforts alongside its sister company. Meanwhile, Cannabix Technologies walked away flush with cash on hand and at least 1,000,000 shares of Algernon Pharmaceuticals with sole pursuit of the University of Florida FAIMS agreement.
I see history repeating itself...and potentially headed for the final BIG CLIFF without positive data from a years long drawn out flip flop management "Decision" to pursue a standalone Chronic Cough study. A study which continues to have the strongest preclinical data of any angle in Algernon Pharmaceuticals so-called Repurposed Drugs "Phase 2" pipeline. Yeah, five years into it Moreau now wants to know if Ifenprodil is a billion dollar drug based on Bellus Health doing their job for their shareholders by getting after a sitting duck. It remains an answer everyone could have easily gotten back in 2021 versus being a Lane Duck. Think of all the destructive dilution of the company they could have avoided had they not flip flopped throughout their leadership existence?
Oh helll...I forgot. Nevermind the past. It's just too hard to deal with as the company moved forward < or > backwards. You decide.
Please do not confuse/conflate due diligence with a scolding.
I'm all ears if there's any rebuttal to what I continue to speak on.
^That being the overall performance of Algernon Pharmaceuticals Inc.
My texting fingers always point towards Algernon Pharmaceuticals management and its Board of mis-Directors.
Thus, with all of the nonsense orchestrated (Big Top performance acts) by corporate from year to year...
The entire lot of them should be given a modest (@ best/boot) severance package.
OAN: Correction to my previous post - "...simply take the current outstanding shares and multiply it by 200 (Two Hundred).
M$
Postscript
Corporate Can Shill @ Will
but...
Just Remember: Anyone wanting to keep track of how many shares of Algernon Pharmaceuticals have been diluted by Moreau - simply take the current outstanding shares and multiply it by 2 (Two). That is the complete representation of true shares issued when you factor in both the 2 to 1 & 100 to 1 Reverse Splits under Moreau's reign. Thus, Moreau has issued upwards of 500,000,000 shares (Five Hundred Million) to date, not including fire sale warrants. I think you still have an offering on the table in Canada to raise money for the "parent" company. You also have the Camouflaged Dilution Deal to raise 10M USD for the "subsidiary" company. When you put the two companies together with combined shares, Moreau will have diluted the entire company by 1,200,000,000 (One Billion Two Hundred Thousand) outstanding shares, not including fire sale warrants. ^That's the full picture you are facing moving forward, if not actually backwards < > ?
M$
News Flash ! Phase 1's DO NOT move the needle.
You will most likely realize any potential gains from the DMT angle by buying the PRIVATE shares of Algernon Neuroscience not AGN/PF.
Also, a Phase 2 data readout from Algernon Pharmaceuticals pipeline will not be realized until maybe 2027 or 2028. That's a looooooong time coming.
Just WOW.
Management pulled the fast one of all fast ones (almost) by pulling DMT out from under shareholders right when the prancing peacock (CEO) is about to go full cockadoodledoo with pennyland messaging.
Incredible, the amount of abuse shareholders have taken, but it's all for "profits". Meanwhile, the stock has fallen 90+% since the "65% chance of success" COVID-19 Hail Mary Data Readout.
Algernon Pharmaceuticals is a long ride on the short bus heading for another cliff. Can anyone see how AlphaNorth has become your worst enemy/biggest obstacle to uplisting to NASDAQ IF EVER? AlphaNorth's 13% hold violates NASDAQ uplisting rules.
To CEO...DUH!
You think AlphaNorth is done buying?!
They will buy up Algernon Neuroscience as well. When the dust from going over the final cliff settles, it will be Algernon Pharmaceuticals on the outs and Algernon Neuroscience moving forward as if YOU PEOPLE never existed.
Yeah, "management" allowed a relatively unknown fund grab you by the tail and spin you/pin you to a bottomless penny stock exchange rife with misdeeds as witnessed by Algernon Pharmaceuticals management and endless conflicts of interest from year to year.
Algernon Pharmaceuticals is a disastrous story through and through. It's the people one invests in more than the process. Wall Street gets it! So, what now? Your CEO finally had a longtime coming lightbulb/cone to Jesus moment to just pursue a standalone chronic cough clinical trial after only moments before telling everyone in black and white they made a "DECISION" to go with IPF + associated cough. That was the plan.
^That Man...Moreau...is a mess of a CEO.
Hav @ it
M$
Your Current (4th) CEO Has Diluted AGNPF 12.5 Times Over Within 4 Years. Not Including Any Offerings To Date.
In Other Words, The Company Has Been Diluted By 1250%
Carry On...
IMO, the "Decision" to pursue a Stand-alone Chronic Cough Study in the same manner as Bellus Health is very significant and positive news. Mirroring Bellus Health (US$1B market cap) offers a potential path out of Dante's Inferno potentially years before Algernon Pharmaceuticals original plan to pursue very sick Idiopathic Pulmonary Fibrosis with cough patients. Albeit, it likely won't be a study conducted in the USA with a 1 year timeline from start to finish, I believe it's still the BEST decision ever made along the treacherous path of Algernon Pharmaceuticals Inc.
Child's Play
M$
Meanwhile...Sub $1 is closer to Earth. EOM. Money Shot
SISTER COMPANY ALGERNON PHARMACEUTICALS ENDORSES "INVESTMENT EXPERT" WHOSE A KNOWN NEO-NAZI
Expert Investor Rates Algernon Pharmaceuticals as an Immediate BuySeptember 2, 2023
algernonpharmaceuticals.com/expert-investor-rates-algernon-pharmaceuticals-as-an-immediate-buy/
POPULAR INVESTMENT ADVISER CHRIS TEMPLE HAS NEO-NAZI TIES
www.splcenter.org/fighting-hate/intelligence-report/2003/popular-investment-adviser-chris-temple-has-neo-nazi-ties
ANTI-SEMITIC INVESTMENT ADVISER SENTENCED TO PRISON
www.splcenter.org/fighting-hate/intelligence-report/2004/anti-semitic-investment-adviser-sentenced-prison
The Inside Man
ALGERNON PHARMACEUTICALS ENDORSES "INVESTMENT EXPERT" WHOSE A KNOWN NEO-NAZI
Expert Investor Rates Algernon Pharmaceuticals as an Immediate BuySeptember 2, 2023
https://algernonpharmaceuticals.com/expert-investor-rates-algernon-pharmaceuticals-as-an-immediate-buy/
POPULAR INVESTMENT ADVISER CHRIS TEMPLE HAS NEO-NAZI TIES
https://www.splcenter.org/fighting-hate/intelligence-report/2003/popular-investment-adviser-chris-temple-has-neo-nazi-ties
ANTI-SEMITIC INVESTMENT ADVISER SENTENCED TO PRISON
https://www.splcenter.org/fighting-hate/intelligence-report/2004/anti-semitic-investment-adviser-sentenced-prison
Any Sympathizers?
ALGERNON PHARMACEUTICALS ENDORSES "INVESTMENT EXPERT" WHOSE A KNOWN NEO-NAZI
Expert Investor Rates Algernon Pharmaceuticals as an Immediate BuySeptember 2, 2023
https://algernonpharmaceuticals.com/expert-investor-rates-algernon-pharmaceuticals-as-an-immediate-buy/
POPULAR INVESTMENT ADVISER CHRIS TEMPLE HAS NEO-NAZI TIES
https://www.splcenter.org/fighting-hate/intelligence-report/2003/popular-investment-adviser-chris-temple-has-neo-nazi-ties
ANTI-SEMITIC INVESTMENT ADVISER SENTENCED TO PRISON
https://www.splcenter.org/fighting-hate/intelligence-report/2004/anti-semitic-investment-adviser-sentenced-prison
Any Sympathizers?
Jake Freeman Is A Genius
youtu.be/XKLzY3LAXxs
Barrow Debate Letter
mindmed.zone/barrow-letter
M$
I wish I knew that before I bought a 30 day subscription. The list of features is convoluted at best. The guy who sells the subscription was no help. He went down the road of emails and seemed not to know what the word messaging meant. Very disappointing experience to get at the facts.
Thank you.
M$
BINGO!!!
"Reading entire messages 10/50/100 at a time"
- or -
"Viewing Message by Author - 50 at a time"
I'm interested primarily in the latter.
That's exactly what I'm talking about. The entire time I've posted at ihub (Circa 2015), I've been an on and off subscriber. I haven't freeloaded the entire time. However, I don't recall ever seeing the ability to look at multiple posts as stated under the paid subscriber. The questions I still have is is that just for the 1st 50 posts or can I pick any series of posts from my history of posts? Also, does the "Message by Author" allow viewing the entire post or is it just the subject line and I still need to open individual posts to see the entire message? You already can see 40 posted subjects without a subscription. It seems like the wording is different for reading the message board versus your own posts. I'd imagine folks out there who are subscribers have the answer. Weird nobody else wants to chime in here.
I hope I'm making sense here. Thank you,
M$
Thank you for the replies. What I was getting at is having the ability to have all the posts open up at one time versus one at a time. That's what I thought would be considered Expanded Mode. Otherwise, there is no Expanded Mode. If I go to other investor sites I can pull up my history of posts and they all open up at once from most recent to last. I could print it like a book without manual labor. It would take who knows how long to open every post I've got to see the overall content and potentially print it. Maybe that's something the ihub website wizards can look into for the future of user ease? Keeping up with the Jones-es.
Peace
M$
Sounds good and Dr. Freeman explained the path to going straight to Phase 3 based on all the other successful clinical work already done. It just takes a growing voice of shareholders to turn the slow boat around. I think management is arrogant in their ways and will be reluctant to speed things up. Barrow even talks at a snails pace. They will continue diluting the company to their benefit. Reverse Split shareholders will be in a world of hurt as time rolls bye bye.
Peace.
M_
Yeah...I'd expect a shallow response hanging on by the thread of one word.. Let's just skip the fact Dr. Freeman says MindMed can SKIP OVER Phase 2b and go directly to a Phase 3. Some just love the slow thinking of it all.
Merriam-Webster